AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)
Phase 3
Completed
- Conditions
- Seasonal Allergic RhinitisHay Fever
- First Posted Date
- 2006-03-22
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 660
- Registration Number
- NCT00305487
- Locations
- 🇺🇸
Altana Pharma/Nycomed, Milwaukee, Wisconsin, United States
Fast Titration in the Treatment of Schizophrenia, Taiwan
Phase 3
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2006-03-20
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT00304473
- Locations
- 🇨🇳
Research Site, Taoyuan, Taiwan
Comparative Study of Oestradiol Suppression: Zoladex 10.8mg/3 Month vs. 3.6mg/Month in ER +ve EBC Pre-menopausal Patients
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2009-12-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 170
- Registration Number
- NCT00303524
- Locations
- 🇯🇵
Research Site, Utsunomiya, Japan
Efficacy of Quetiapine in Generalised Social Anxiety Disorder
Phase 3
Terminated
- Conditions
- Social Anxiety Disorder
- First Posted Date
- 2006-03-15
- Last Posted Date
- 2011-01-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 50
- Registration Number
- NCT00302770
- Locations
- 🇳🇱
Research Site, Utrecht, Netherlands
3 Years of Anastrozole vs. no Treatment as Extended Adjuvant Therapy for Postmenopausal Women With Breast Cancer
Phase 3
Completed
- Conditions
- Breast Neoplasms
- First Posted Date
- 2006-03-09
- Last Posted Date
- 2009-05-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 856
- Registration Number
- NCT00300508
- Locations
- 🇦🇹
Research site, Hollabrunn, Austria
🇦🇹Research Site, Zams, Austria
GALLEX 4 - Long-Term Extension Study to Evaluate Tesaglitazar Therapy in Patients With Type 2 Diabetes
Phase 3
Terminated
- Conditions
- Type 2 Diabetes
- First Posted Date
- 2006-03-08
- Last Posted Date
- 2008-03-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 400
- Registration Number
- NCT00300105
- Locations
- 🇹🇭
Research Site, Bangkok, Thailand
A Study of IRESSA in Relapsed and Refractory Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Small Cell Lung Cancer
- First Posted Date
- 2006-03-03
- Last Posted Date
- 2008-06-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 56
- Registration Number
- NCT00298688
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124)
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2006-02-28
- Last Posted Date
- 2017-01-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1523
- Registration Number
- NCT00297102
- Locations
- 🇬🇧
Altana Pharma/Nycomed Investigational Site, Vale of Glamorgan, United Kingdom
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125)
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2006-02-28
- Last Posted Date
- 2016-11-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1568
- Registration Number
- NCT00297115
- Locations
- 🇪🇸
Altana Pharma/Nycomed Investigational Site, Valencia, Spain
Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease
- First Posted Date
- 2006-02-27
- Last Posted Date
- 2011-09-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 353
- Registration Number
- NCT00296374
- Locations
- 🇷🇴
Research Site, Timisoara, Romania
🇦🇷Reasearch Site, La Plata, Argentina
🇭🇺Research site, Gyula, Hungary
© Copyright 2025. All Rights Reserved by MedPath